CHILDRENS HOSPITAL LOS ANGELES
The Sunshine Act requires manufacturers to report payments to teaching hospitals as institutions, separately from payments to individual physicians. These figures are money reported to the hospital itself — most of it research funding and grants, not compensation to any named doctor.
- Total reported
- $50.9M
- Transactions
- 11,415
- Companies
- 40
- Average per transaction
- $4,457
Who reported the payments
| Takeda Pharmaceuticals U.S.A., Inc. | $7,084,303 |
| Pfizer | $3,986,107 |
| Amgen | $3,084,139 |
| Eli Lilly | $2,279,789 |
| Ultragenyx Pharmaceutical Inc. | $2,071,150 |
| Mylan Inc. | $2,000,000 |
| Bristol Myers Squibb | $1,653,656 |
| Jubilant Draximage Inc. | $1,637,573 |
| Adaptive Biotechnologies Corporation | $1,567,462 |
| Novartis | $1,557,213 |
| United Therapeutics Corporation | $1,370,791 |
| Novo Nordisk AS | $1,291,853 |
| Vertex | $1,172,117 |
| Gilead | $1,066,922 |
| Regeneron | $1,003,741 |
| Merck | $846,576 |
| Jazz Pharmaceuticals Inc. | $817,125 |
| Luminex Corporation | $814,524 |
| AstraZeneca | $799,100 |
| Boehringer Ingelheim | $736,109 |
| Genentech, Inc. | $723,504 |
| Kls-martin L.p. | $717,858 |
| Abbott | $619,769 |
| Chromacode, Inc | $593,615 |
| Biofire Diagnostics, LLC | $592,126 |
| Janssen Research & Development, LLC | $545,324 |
| Astrazeneca UK Limited | $512,998 |
| GW Research Limited | $507,014 |
| Sanofi | $499,128 |
| Sanofi US Services Inc. | $420,473 |
| Sarepta Therapeutics, Inc. | $413,887 |
| Mirum Pharmaceuticals, Inc. | $406,926 |
| Neurocrine Biosciences, Inc. | $354,391 |
| Shire North American Group Inc | $333,335 |
| BD | $311,458 |
| Grifols Shared Services North America, Inc. | $282,558 |
| Progenics Pharmaceuticals, Inc. | $270,262 |
| National Marrow Donor Program | $256,647 |
| Spark Therapeutics, Inc. | $250,396 |
| E.r. Squibb & Sons, L.L.C. | $243,978 |